RT Journal Article SR Electronic T1 Single-dose SARS-CoV-2 vaccine in a prospective cohort of COVID-19 patients JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.05.25.21257797 DO 10.1101/2021.05.25.21257797 A1 Marit J. van Gils A1 Hugo D. van Willigen A1 Elke Wynberg A1 Alvin X. Han A1 Karlijn van der Straten A1 Anouk Verveen A1 Romy Lebbink A1 Maartje Dijkstra A1 Judith A. Burger A1 Melissa Oomen A1 Khadija Tejjani A1 Joey H. Bouhuijs A1 Brent Appelman A1 Ayesha H.A. Lavell A1 Meliawati Poniman A1 Tom G. Caniels A1 Ilja Bontjer A1 Lonneke A. van Vught A1 Alexander P.J. Vlaar A1 Jonne J. Sikkens A1 Marije K. Bomers A1 Rogier W. Sanders A1 Neeltje A. Kootstra A1 Colin Russell A1 Maria Prins A1 Godelieve J. de Bree A1 Menno D. de Jong A1 RECoVERED Study Group YR 2021 UL http://medrxiv.org/content/early/2021/05/25/2021.05.25.21257797.abstract AB Background The urgent need for, but limited availability of, SARS-CoV-2 vaccines worldwide has led to widespread consideration of dose sparing strategies, particularly single vaccine dosing of individuals with prior SARS-CoV-2 infection.Methods We evaluated SARS-CoV-2 specific antibody responses following a single-dose of BNT162b2 (Pfizer-BioNTech) mRNA vaccine in 155 previously SARS-CoV-2-infected individuals participating in a population-based prospective cohort study of COVID-19 patients.Participants varied widely in age, comorbidities, COVID-19 severity and time since infection, ranging from 1 to 15 months. Serum antibody titers were determined at time of vaccination and one week after vaccination. Responses were compared to those in SARS-CoV-2-naive health care workers after two BNT162b2 mRNA vaccine doses.Results Within one week of vaccination, IgG antibody levels to virus spike and RBD proteins increased 27 to 29-fold and neutralizing antibody titers increased 12-fold, exceeding titers of fully vaccinated SARS-CoV-2-naive controls (95% credible interval (CrI): 0.56 to 0.67 v. control 95% CrI: −0.16 to −0.02). Pre-vaccination neutralizing antibody titers had the largest positive mean effect size on titers following vaccination (95% CrI (0.16 to 0.45)). COVID-19 severity, the presence of comorbidities and the time interval between infection and vaccination had no discernible impact on vaccine response.Conclusion A single dose of BNT162b2 mRNA vaccine up to 15 months after SARS-CoV-2 infection provides neutralizing titers exceeding two vaccine doses in previously uninfected individuals. These findings support wide implementation of a single-dose mRNA vaccine strategy after prior SARS-CoV-2 infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Netherlands Organization for Scientific Research (NWO) ZonMw (RECoVERED grant agreement no. 10150062010002 to M.D.d.J. S3 study grant agreement no. 10430022010023 to J.J.S. and Vici grant no. 91818627 to R.W.S.) The Bill & Melinda Gates Foundation (grant no. INV-002022 and INV008818 to R.W.S. and INV-024617 to M.J.v.G.) Amsterdam UMC through the AMC Fellowship (to M.J.v.G.) and the Corona Research Fund (to M.K.B.) The European Research Council (no. 818353 to C.A.R.) The European Union Horizon 2020 program (RECoVER grant no. 101003589 to M.D.d.J) The Public Health Service of Amsterdam (Research & Development grant no. 21-14 to M.P.)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The RECoVERED study, including the vaccine substudy, and the S3 study were approved by the medical ethical review board of the Amsterdam University Medical Centers (NL73759.018.20 and NL73478.029.20, respectively). All participants provided written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData supporting the findings in this manuscript are available from the corresponding author upon request.